Alkermes Plc EPS Soars Past Forecasts
(NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported robust financial results, beating analyst estimates with a non-GAAP EPS of $1.04 against an expected $0.76. Revenue also exceeded projections, reaching $430 million compared to the $379 million forecast.
Overall, the company delivered a strong quarter, driven by significant sales from its proprietary product portfolio, although challenges in manufacturing and royalties remain.
Source: Alkermes. Analyst estimates for the quarter provided by FactSet.
Source Fool.com
Alkermes plc Stock
?
0.000%
Alkermes plc is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 37 € shows a positive potential of 30.28% compared to the current price of 28.4 € for Alkermes plc.
